Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic.

Viking Therapeutics' VK2735 is positioned as a potential GLP-1/GIP weight-loss challenger, with analysts forecasting $141 million of revenue in 2028 and $1.3 billion in 2030 against its current $3.5 billion market capitalization. Injectable VK2735 produced 14.7% peak weight loss at 13 weeks in phase 2, though this is not directly comparable with Eli Lilly's 20.9% tirzepatide result at 72 weeks in phase 3. The key risk is oral VK2735 tolerability: 20% of participants discontinued in its phase 2 study due to adverse events, prompting Viking to adjust dose, tablet size, and tablet count for phase 3 trials.

Analysis

VKTX is priced as a binary platform asset despite a catalyst gap: the next truly value-defining readouts are years away, while the nearer maintenance data is too small to resolve either durable efficacy or commercial tolerability. With sell-side targets implying substantial probability of successful injectable and oral commercialization, the relevant downside is not simply a failed trial; it is a phase 3 design that trades efficacy for gastrointestinal tolerability and resets peak-sales assumptions before pivotal efficacy is known.

The oral opportunity is strategically more important than incremental revenue estimates suggest because it determines whether VKTX can participate in maintenance therapy rather than compete only for injectable initiation. However, an oral product that requires multiple tablets, slower titration, or materially lower exposure than injectables may be commercially inferior even if statistically successful. That would favor LLY, whose scale, payer contracting capability, and prescriber familiarity can turn modest clinical parity into durable share retention; NVO is more exposed at the margin if convenience becomes the key competitive variable.

Consensus appears to extrapolate early weight-loss velocity into a differentiation claim, but cross-trial comparisons are particularly unreliable where titration schedules and discontinuation differ. The contrarian view is that rapid onset may be economically valuable only if it improves persistence; otherwise it can increase adverse-event discontinuation and worsen real-world outcomes. Over the next 1-3 months, updates on phase 3 dose selection, tablet burden, and discontinuation management matter more than a small maintenance study; over 6-18 months, competitive read-throughs from next-generation incretins and oral obesity programs could compress VKTX's strategic premium well ahead of its own pivotal data.

Key Decisions for Investors

• Do not initiate a core VKTX long ahead of pivotal clarity; treat it as a catalyst watchlist name. Reassess only after disclosed oral phase 3 dose/titration and tablet-count details support a credible discontinuation improvement versus prior experience.
• For biotech exposure over the next 3-6 months, prefer long LLY versus VKTX as a relative-value expression: LLY monetizes current demand and has lower clinical-duration risk, while VKTX carries multiple compression risk if oral positioning weakens. Falsify if LLY's obesity growth or supply commentary materially deteriorates.
• If owning VKTX, cap gross exposure as a venture-style position and use defined-risk downside protection extending through oral trial-design disclosure; avoid short-dated options because the key fundamental catalysts are not imminent.
• Set an alert for any increase in VKTX cash burn, partnership/M&A language, or revised development timing. A financing need before meaningful pivotal de-risking would raise dilution risk and undermine the funded-through-2028 narrative.